Loading clinical trials...

PLM60 for Peripheral T Cell Lymphoma (PTCL) | Clinical Trials | Clareo Health

WITHDRAWNPHASE1/PHASE2

PLM60 for Peripheral T Cell Lymphoma (PTCL)

A Randomized Phase 1-2 Study of PLM60 in Patients With Peripheral T-Cell Lymphoma

NCT03553914•Conjupro Biotherapeutics, Inc.

Summary

This is a Phase 1-2, randomized, multicenter, open label study of PLM60 administered via intravenous (IV) infusion in 28 day treatment cycles to adult participants with relapsed or refractory Peripheral T Cell Lymphoma (PTCL).

Detailed Description

The study is designed to identify and characterize the safety, tolerability, efficacy, and the PK profile of PLM60 in patients with relapsed or refractory PTCL. Phase 1 will explore multiple dose levels and select a single dose level in Phase 2 to more effectively assess efficacy in the PTCL population. It is anticipated that up to approximately 30 participants will be enrolled during Phase 1. The actual number enrolled, however, will depend on the number of dose-limiting toxicity (DLT)-evaluable participants that complete the first cycle of therapy. Phase 2 will enroll up to 34 participants at the RP2D, some of whom will have been enrolled during Phase 1. Consequently, up to approximately 55 participants will be treated in the study as a whole.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Signed informed consent prior to study-related procedures
•2. Patients with histologically confirmed relapsed or refractory PTCL, who were treated with at least 2 lines of standard therapy and for whom there is no known effective therapy.
•3. Recovered from all toxicity from prior anticancer therapy based on clinical evaluation/ judgement of the Investigator
•4. Participants must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.
•5. Participants who have sufficient baseline organ function by laboratory evaluations
•6. Left ventricular ejection fraction (LVEF) ≥ 50%
•7. Life expectancy ≥ 16 weeks
•8. Women of childbearing potential must have a negative pregnancy test prior to study entry, and agree to use adequate contraception from study entry through at least 3 months after the last dose of study drug
•9. A male participant must agree to use adequate contraception; or female sexual partner who uses adequate contraception measures from study entry through at least 3 months after the last dose of study drug
•1. Involved lymph nodes or masses should be measurable in at least 2 perpendicular dimensions and be ≥ 1.5 cm in the longest of the perpendicular dimensions (based on Lugano Classification)
+1 more criteria

Exclusion Criteria

•1. Participants with a history of allergy to anthracyclines or liposomal drugs
•2. Prior treatment with mitoxantrone, any anthracycline, or anthacenedione
•3. Treatment with doxorubicin (with the exception of pegylated liposomal doxorubicin) with a total cumulative dose \> 300 mg/m2, or epirubicin with a total cumulative dose \> 500 mg/m2
•4. Investigational treatment within 4 weeks of the start of PLM60
•5. Prior allogeneic stem cell transplantation
•6. Current symptomatic (uncontrolled) central nervous system tumor involvement
•7. Certain types of cardiac impairment as defined in the protocol at the time of enrolment
•8. Any concurrent active malignancy or concurrent malignancy diagnosis with less than 12 months disease free interval
•9. Participants with evidence of an active infection
•10. Participants with active bleeding
+1 more criteria

Locations (2)

Gabrail Cancer Center

Canton, Ohio, United States

Gabrial Cancer Center

Canton, Ohio, United States

Key Dates

Start Date

January 1, 2021

Primary Completion Date

January 1, 2024

Completion Date

January 1, 2025

Last Updated

October 19, 2020

Conditions

Peripheral T Cell Lymphoma

Interventions

PLM60

DRUG

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

NCT07389616

Peripheral T Cell Lymphoma

View study

RECRUITINGPHASE2

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

NCT07356245

T-cell LymphomaGraft Versus Host Disease+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 19, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PLM60 for Peripheral T Cell Lymphoma (PTCL)

Inclusion Criteria

Exclusion Criteria

A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

T Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma